BREAKING
Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 2 days ago Zoom Communications Q4 2025 Earnings Results 3 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 3 days ago Synopsys Q1 2026 Earnings Results 3 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 3 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 3 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 4 days ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 5 days ago Apple Inc. (AAPL) Surges 5.1% — Developing Story 5 days ago Mastercard Incorporated (MA) Drops 5.6% — Developing Story 5 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 2 days ago Zoom Communications Q4 2025 Earnings Results 3 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 3 days ago Synopsys Q1 2026 Earnings Results 3 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 3 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 3 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 4 days ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 5 days ago Apple Inc. (AAPL) Surges 5.1% — Developing Story 5 days ago Mastercard Incorporated (MA) Drops 5.6% — Developing Story 5 days ago
ADVERTISEMENT
AlphaGraphs

Vertex Pharmaceuticals (VRTX) Earnings: 2Q23 Key Numbers

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net income was $915.7 million, or $3.52 per share, compared to $810.5 million, or $3.13 per share, last year. Adjusted EPS was $3.89. For the full year of 2023, CF product revenues are expected […]

$VRTX August 2, 2023 1 min read
NYSE
$VRTX · Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net income was $915.7 million, or $3.52 per share, compared to $810.5 million, or $3.13 per share, last year. Adjusted EPS was $3.89. For the full year of 2023, CF product revenues are expected […]

· August 2, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year.

Net income was $915.7 million, or $3.52 per share, compared to $810.5 million, or $3.13 per share, last year. Adjusted EPS was $3.89.

For the full year of 2023, CF product revenues are expected to range between $9.7-9.8 billion.

Prior performance

ADVERTISEMENT